Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
On January 10, 2006, administrators notified the company of an increase in interests in Ordinary Share ADRs for specific individuals. This increase resulted from the reinvestment of dividends paid to shareholders on January 5, 2006, at a price of $52.29 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding insider trading rules (Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b)).
Important Facts for Investors
- Transaction Type: Increase in ADR holdings via dividend reinvestment.
- Transaction Price: $52.29 per ADR.
- Key Participants: Dr. W. Calhoun, Dr. J. P. Garnier, Mr. D. Phelan, Dr. D. Stout, and Mr. J. Ziegler.
- Dividend Date: January 5, 2006.
- Notification Date: January 10, 2006.